2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Sofituzumab vedotin

Sofituzumab vedotin  (Synonyms: DMUC5754A)

Cat. No.: HY-P99593 Purity: 98.72%
COA

Molarity Calculator

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer.

For research use only. We do not sell to patients.

Sofituzumab vedotin Chemical Structure

Sofituzumab vedotin Chemical Structure

CAS No. : 1418200-58-4

Size Price Stock Quantity
1 mg USD 950 In-stock
5 mg USD 2380 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Sofituzumab vedotin:

Sofituzumab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].

In Vitro

Sofituzumab vedotin (DMUC5754A) is an antibody–drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl[2].
Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16TMlong cells proliferation in a dose-dependent manner[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sofituzumab vedotin Related Antibodies

Cell Proliferation Assay[3]

Cell Line: OVCAR-3 and PC3/MUC16TMlong cells
Concentration: 0.1-10000 ng/mL
Incubation Time: 3 days for OVCAR-3 and 5 days for PC3/MUC16TMlong
Result: Significantly inhibited cell proliferation above 100 ng/mL.
In Vivo

Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts[3]
Dosage: 2.8 mg/kg
Administration: IV, once weekly for 4 total doses
Result: Improved survival.
Animal Model: Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads[3]
Dosage: 2 mg/kg
Administration: IV, once weekly for 3 total doses
Result: Significantly decreased the tumor volume.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Sofituzumab vedotin]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sofituzumab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sofituzumab vedotin1418200-58-4DMUC5754AAntibody-Drug Conjugates (ADCs)Antibody-Drug Conjugatesovarian cancerpancreatic cancerOVCAR-3PC3/MUC16TMlongInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sofituzumab vedotin
Cat. No.:
HY-P99593
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.